Remember that this information is intended as a general guide and should not replace personalized medical advice from a healthcare provider
,
And TRANSCEND-T2D-1, part of a separate three-trial diabetes-specific program, confirmed -2.0% HbA1c reduction and 16.8% weight loss in 537 type 2 diabetes patients (topline March 2026, published in The Lancet, June 2026)
Total gross commercial spending on GLP-1 drugs in Massachusetts is expected to exceed $270 million in 2023, more than double the $125 million in spending in 2022, according to presentation slides shared at a commission meeting last week
BPC-157 has accumulated more than 150 peer-reviewed publications spanning tendon and ligament repair, gastrointestinal protection, vascular biology, and central nervous system trauma research since the original Zagreb characterisation by Sikiric and colleagues
Eligibility and prescription required